Authors: A Ducancelle M C Legrand A Pivert P Veillon H Le GuillouGuillemette M A De Brux A BebyDefaux G Agius S Hantz S Alain L Catala P Descamps E Postec H Caly F CharlesPétillon F Labrousse F Lunel C Payan
Publish Date: 2014/03/13
Volume: 290, Issue: 2, Pages: 299-308
Abstract
Cervical cancer is caused by persistent infection with highrisk human papillomavirus HRHPV Conventional human papillomavirus HPV testing requires cervical sampling However vaginal and urine selfsampling methods are more acceptable for patients and result in increased participation when they are available in screening programs In this context we have developed a noninvasive screening method via the detection of HPV DNA in urine samplesPaired urine and cervical specimens were collected and analyzed from 230 of 245 women participating in the previously described prospective PapU study HPV DNA detection and quantification were performed using a realtime PCR method with short fragment PCR primers Genotyping was carried out using the INNOLiPA HPV genotyping assayThe prevalence of HPV in the 230 paired urine and cervical smear samples was 42 and 49 respectively Overall agreement for HPV positivity and negativity between the paired samples was 90 κ = 080 High HPV viral load in both cervical and urine samples was associated with cytological abnormalities HPVpositive women were mostly infected with HRHPV types The agreement between high and lowrisk HPV LRHPV detection in both samples was 97 κ = 095 for HRHPV and κ = 097 for LRHPVWe express our thanks to D Jolivet Angers and C Dolou Brest for their helpful assistance in management A Pivert B Mosset for their technical help and K L Erwin for proofreading the English manuscript The PapU study was initiated by the Angers University hospital with grants from the French Ligue Contre le Cancer MaineetLoire committee Professor Larra
Keywords: